

First Look Note | 4Q24

UAE Equity Research

Sector: Banking

Market: DFM

Commercial Bank of Dubai (CBD)

Strong growth non-funded income and lower impairments boosted profitability

| Current Price (AED): | Target Price (AED): | Upside/Downside (%) | Rating: |
|----------------------|---------------------|---------------------|------------|
| 7.66 | 8.55 | +12% | ACCUMULATE |


- Net advances grew 11.7% YOY and 1.4% QOQ to AED 93.1 Bn in 4Q24
- Customer deposits increased 10.5% YOY but declined 1.1% QOQ to AED 97.6 Bn in 4Q24, also CASA ratio stood at 49% in 4Q24.
- Calculated NIMs declined 21 bps YOY and remained unchanged on QOQ basis to 3.0% in 4Q24.
- CBD's asset quality improved with a decline in NPL ratio from 5.0% in 3Q24 to 4.4% in 4Q24.
- Capitalization remained strong with a CAR of 15.6% and CET 1 of 12.4% in 4Q24.
- Board of directors proposed a dividend of AED 0.5074 per share for 2024 amounting to AED 1,515 Mn with a strong dividend yield of 6.6%.

4Q24 Net Profit in line with our estimate

Commercial Bank of Dubai ("CBD, "the Bank") recorded a growth in net profit of 11.9% YOY to AED 799 Mn in 4Q24, in line with our estimate of AED 807 Mn. The increase in net profit is driven by growth in net funded income and non-funded income along with a decline in impairments partially offset by an increase in operating expenses and income tax charges.

P&L Highlights

CBD's funded income grew 4.5% YOY to AED 1,882 Mn in 4Q24, mainly due to growth in loan book and other interest-earning assets partially offset by a decline in asset yield. On the other hand, funded expenses arew 5.3% YOY to AED 933 Mn in 4024 owing to an increase in interestbearing liabilities. Thus, net funded income rose 3.7% YOY to AED 950 Mn in 4Q24. CBD's fees and commission income grew 24.3% YOY to AED 265 Mn in 4Q24 owing to an increase in fees from syndication and higher transaction banking activity. Trading income grew marginally 3.2% YOY to AED 84 Mn in 4024. Other non-funded income arew from AED 11 Mn in 4Q23 to AED 28 Mn in 4Q24. Thus, CBD's total non-funded income rose 23.2% YOY to AED 377 Mn in 4Q24. Thus, CBD's total operating income rose 8.6% YOY to AED 1,326 Mn in 4Q24. Further, G&A expenses grew 10.0% YOY to AED 366 Mn in 4024 due to a rise in staff cost caused by increased regulatory control and governance coupled with higher other operating expenditures attributable to investments in technology, digitisation, inflationary, and regulatory compliance. As a result, total operating expenses rose 11.4% YOY to AED 386 Mn in 4024. Additionally, impairments on loans, advances and Islamic financing declined 59.9% YOY to AED 107 Mn in 4Q24. The recoveries on loans and advances and Islamic financing declined significantly from AED 102 Mn in 4Q23 to AED 44 Mn in 4Q24. In addition, the Bank incurred a corporate tax expense of AED 76 Mn in 4Q24, owing to the introduction of UAE corporate tax.



| Stock Information | | | | | |
|---------------------------|-----------|--|--|--|--|
| Market Cap (AED, mn) | 22,866.57 | | | | |
| Paid Up Capital (mn) | 2,985.19 | | | | |
| 52 Week High | 8.99 | | | | |
| 52 Week Low | 5.60 | | | | |
| 3M Avg. daily value (AED) | 276,293 | | | | |

| 4Q24 Result Review (AED, mn) | | | | | |
|------------------------------|---------|--|--|--|--|
| Total Assets | 140,175 | | | | |
| Total Liabilities | 122,751 | | | | |
| Total Equity | 17,425 | | | | |
| Total Deposits | 97,563 | | | | |
| Net Profit | 799 | | | | |

| Financial Ratios | |
|--------------------------|-------|
| Dividend Yield (12m) | 5.79 |
| Dividend Pay-out (%) | 52.27 |
| Price-Earnings Ratio (x) | 7.94 |
| Price-to-Book Ratio (x) | 1.50 |
| Book Value (AED) | 5.10 |
| Return on Equity (%) | 20.12 |

| Stock Performance | | | | | |
|------------------------|--------|--|--|--|--|
| 5 Days | 6.09% | | | | |
| 1 Months | 6.39% | | | | |
| 3 Months | 6.24% | | | | |
| 6 Months | 20.25% | | | | |
| 1 Year | 36.06% | | | | |
| Month to Date (MTD%) | -0.52% | | | | |
| Quarter to Date (QTD%) | 6.69% | | | | |
| Year to Date (YTD%) | 6.69% | | | | |



Balance Sheet Highlights

CBD's net advances rose 11.7% YOY and 1.4% QOQ to AED 93.1 Bn in 4Q24. The Bank witnessed an increase in credit towards all sectors except hospitality, real estate, financial, construction, and individual loans compared to 4Q23. Moreover, the Bank's total assets rose 8.7% YOY to 140.2 Bn in 4Q24 but remained unchanged on QOQ basis. Customer deposits recorded a healthy growth of 10.5% YOY but declined 1.1% QOQ to AED 97.6 Bn in 4Q24. The headline loan-to-deposit ratio increased to 95.4% in 4Q24 compared to 93.0% in 3Q24. Additionally, the Bank's CASA deposits stood at 49% of total deposits in 4Q24. CBD's total equity rose 10.4% YOY and 3.9% QOQ to AED 17.4 Bn in 4Q24.

Target Price and Rating

We revise our rating on CBD from HOLD to ACCUMULATE with a revised target price of AED 8.55. CBD recorded healthy growth in profitability, surpassing AED 3 Bn in net profit for the first time on the back of a solid increase in net funded and non-funded income along with growth in recoveries in 2024. The Bank's net advances grew 11.7% YOY to AED 93.04 Bn in 4Q24 and further provided loan guidance of mid to high single-digit percentage growth for FY2025. CBD's calculated NIM declined 21 bps YOY to 3.0% in 4Q24 and remained unchanged on QOQ basis. The Bank's deposits recorded a healthy growth of 10.5% YOY but declined 1.1% QOQ to AED 97.6 Bn in 4Q24 resulting in the headline loan-to-deposit ratio of 95.4%. Low-cost CASA deposits constituted 49% of the total customer deposit base, while the balance is made up of time deposits. Cost-to-income ratio grew 73 bps YOY and 339 bps QOQ to 29.1% in 4Q24 due to investment in business growth and digitization coupled with higher staff costs due to regulation. It expects the cost-to-income to be below 28.0% in 2025. Furthermore, the Bank's cost of risk marginally declined 48 bps YOY and 63 bps QOQ to 0.3% in 4Q24, while CBD estimates its cost of risk to remain less than 65 bps in 2025. Additionally, CBD's asset quality improved significantly in 4Q24 with a reported NPL ratio of 4.4% compared to 5.0% in 3Q24. Moreover, the Bank reported coverage increased to 104.2% in 4Q24 from 96.6% in 3Q24. In addition, the Bank maintained a healthy capitalization with a CAR of 15.6% and CET 1 ratio of 12.4% well above the regulatory limits in 4024. The board of directors proposed a dividend of AED 0.5074 per share for 2024 amounting to AED 1,515 Mn with a strong 2024 dividend yield of 6.6%. Thus, based on our analysis, we assign an ACCUMULATE rating on the stock.

CBD - Relative valuation

| (at CMP) | 2020 | 2021 | 2022 | 2023 | 2024 | 2025F |
|----------------|-------|-------|-------|------|------|-------|
| P/E | 20.35 | 17.18 | 13.37 | 8.99 | 7.81 | 7.9 |
| P/B | 2.23 | 1.99 | 1.94 | 1.67 | 1.49 | 1.4 |
| Dividend yield | 2.5% | 3.2% | 3.2% | 5.9% | 6.6% | 6.6% |

FABS Estimates & Co Data



CBD – P&L

| AED mn | 4Q23 | 3Q24 | 4Q24 | 4Q24F | Var. | YOY Ch | QOQ Ch | 2023 | 2024 | Change |
|-----------------------------|-------|-------|-------|-------|--------|--------|--------|--------|--------|--------|
| Funded income | 1,802 | 1,934 | 1,882 | 2,015 | -6.6% | 4.5% | -2.7% | 6,664 | 7,544 | 13.2% |
| Funded expense | -885 | -990 | -933 | -946 | -1.4% | 5.3% | -5.8% | -3,094 | -3,745 | 21.0% |
| Net funded income | 916 | 943 | 950 | 1,069 | -11.2% | 3.7% | 0.7% | 3,570 | 3,799 | 6.4% |
| Fees and commissions | 214 | 277 | 265 | 272 | -2.5% | 24.3% | -4.2% | 935 | 1,115 | 19.3% |
| Trading income | 81 | 84 | 84 | 83 | 0.9% | 3.2% | 0.0% | 323 | 337 | 4.1% |
| Other non-funded income | 11 | 150 | 28 | 54 | -48.7% | NM | -81.6% | 110 | 240 | 117.9% |
| Total non-funded income | 306 | 511 | 377 | 409 | -7.8% | 23.2% | -26.3% | 1,368 | 1,692 | 23.7% |
| Total operating income | 1,222 | 1,454 | 1,326 | 1,478 | -10.3% | 8.6% | -8.8% | 4,938 | 5,491 | 11.2% |
| G&A Expenses | -333 | -358 | -366 | -343 | 6.6% | 10.0% | 2.2% | -1,178 | -1,342 | 13.9% |
| Depreciation & amortization | -14 | -16 | -20 | -17 | 17.9% | 43.4% | 26.3% | -49 | -61 | 23.5% |
| Operating Expenses | -347 | -374 | -386 | -360 | 7.1% | 11.4% | 3.2% | -1,228 | -1,403 | 14.3% |
| Pre provision profit | 875 | 1,081 | 941 | 1,118 | -15.9% | 7.5% | -13.0% | 3,710 | 4,087 | 10.2% |
| Impairments | -266 | -314 | -107 | -309 | -65.5% | -59.9% | -66.0% | -1,094 | -990 | -9.6% |
| Recoveries | 102 | 98 | 44 | 90 | -51.2% | -57.2% | -55.3% | 182 | 257 | 41.3% |
| Impairment on AFS invest. | 3 | -9 | -2 | -9 | -83.3% | NM | -83.1% | -148 | -30 | -79.9% |
| Profit before tax | 714 | 855 | 876 | 889 | -1.4% | 22.6% | 2.4% | 2,650 | 3,325 | 25.5% |
| Corporate tax | 0 | -76 | -76 | -82 | -6.3% | NM | 0.4% | 0 | -295 | NM |
| Net Profit | 714 | 779 | 799 | 807 | -0.9% | 11.9% | 2.6% | 2,650 | 3,030 | 14.3% |

FABS estimate & Co Data

CBD - KPI

| | 4Q23 | 3Q24 | 4Q24 | YOY Ch | QQQ Ch | 2023 | 2024 | Change |
|---------------------|-------|-------|--------|--------|--------|-------|--------|--------|
| Net FI/OI | 75.0% | 64.9% | 71.6% | -338 | 673 | 72.3% | 69.2% | -310 |
| NIM | 3.2% | 3.0% | 3.0% | -21 | 0 | 3.24% | 3.08% | -16 |
| NIS | 2.7% | 2.5% | 2.5% | -21 | 0 | 2.8% | 2.6% | -23 |
| Fees & comms/OI | 17.5% | 19.0% | 20.0% | 253 | 96 | 18.9% | 20.3% | 138 |
| Trading/OI | 6.7% | 5.8% | 6.3% | -33 | 55 | 6.5% | 6.1% | -42 |
| Cost to income | 28.4% | 25.7% | 29.1% | 73 | 339 | 24.9% | 25.6% | 69 |
| Impairment/PPP | 18.4% | 20.9% | 6.9% | -1,149 | -1,399 | 28.6% | 18.6% | -992 |
| NP/OI | 58.5% | 53.5% | 60.3% | 179 | 671 | 53.7% | 55.2% | 151 |
| Cost of Risk | 0.7% | 0.9% | 0.3% | -48 | -63 | 1.02% | 0.74% | -28 |
| Loan-to-deposit | 94.4% | 93.0% | 95.4% | 101 | 240 | 94.4% | 95.4% | 101 |
| NPL – Reported | 6.5% | 5.0% | 4.4% | -211 | -61 | 6.5% | 4.4% | -211 |
| Coverage – Reported | 83.3% | 96.6% | 104.2% | 2,097 | 762 | 83.3% | 104.2% | 2,097 |
| CET1 | 12.5% | 13.4% | 12.4% | -14 | -97 | 12.5% | 12.4% | -14 |
| Capital adequacy | 15.9% | 16.6% | 15.6% | -38 | -99 | 16.0% | 15.6% | -38 |
| ROAE | 19.9% | 20.6% | 20.1% | 19 | -47 | 19.9% | 20.1% | 18 |
| ROAA | 2.2% | 2.2% | 2.3% | 9 | 4 | 2.2% | 2.5% | 27 |

FABS estimate & Co Data

CBD - Key B/S items

| AED mn | 4Q23 | 1Q24 | 2Q24 | 3Q24 | 4Q24 | YOY Ch |
|-------------------|---------|---------|---------|---------|---------|--------|
| Net advances | 83,313 | 86,791 | 89,608 | 91,746 | 93,049 | 11.7% |
| QOQ ch | 0.5% | 4.2% | 3.2% | 2.4% | 1.4% | |
| Total assets | 128,987 | 130,976 | 141,256 | 140,217 | 140,175 | 8.7% |
| QOQ ch | 2.4% | 1.5% | 7.8% | -0.7% | 0.0% | |
| Customer deposits | 88,287 | 90,342 | 99,831 | 98,682 | 97,563 | 10.5% |
| QOQ ch | 2.1% | 2.3% | 10.5% | -1.2% | -1.1% | |
| Total equity | 15,781 | 15,138 | 15,843 | 16,772 | 17,425 | 10.4% |
| QOQ ch | 5.6% | -4.1% | 4.7% | 5.9% | 3.9% | |

FABS estimate & Co Data



Valuation:

We use Residual Income and Relative Valuation (RV) method to value CBD. We have assigned 70% weight to Residual Income, and 30% to RV method.

| Valuation Method | Target | Weight | Weighted Value |
|----------------------------------|--------|--------|----------------|
| | | | |
| Residual Income | 8.91 | 70.0% | 6.24 |
| Relative Valuation (RV) | 7.72 | 30.0% | 2.32 |
| | | | |
| Weighted Average Valuation (AED) | | | 8.55 |
| Current market price (AED) | | | 7.66 |
| Upside/Downside (%) | | | +12% |

1) Residual Income Method:

We have discounted the economic profit/excess equity using the cost of equity of 9.5%. Cost of equity is calculated by using 10-year government bond yield of 5.5%, beta of 0.9 and equity risk premium of 4.3%. Government bond yield is calculated after adding Dubai 10-year CDS spread over 10-year US risk-free rate. Also, assumed a terminal growth rate of 2.0%.

| Sum of PV (AED, Mn) | 3,860 |
|---------------------------------------|--------|
| Terminal value (AED, Mn) | 7,523 |
| Book value of equity (as of Dec 2024) | 15,221 |
| FV to Common shareholders (AED, Mn) | 26,604 |
| No. of share (Mn) | 2,985 |
| Current Market Price (AED) | 7.66 |
| Fair Value per share (AED) | 8.91 |

| (All Figures in AED Mn) | FY 2024E | FY 2025E | FY 2026E | FY 2027E | FY 2028E |
|--------------------------------|----------|----------|----------|----------|----------|
| Net Profit | 2,856 | 2,680 | 2,687 | 2,946 | 2,981 |
| (-) Equity charge | (1,586) | (1,705) | (1,826) | (1,971) | (2,111) |
| Excess Equity | 1,270 | 975 | 861 | 975 | 871 |
| Discounting Factor | 0.91 | 0.83 | 0.76 | 0.70 | 0.64 |
| Present Value of Excess Equity | 1,160 | 813 | 656 | 678 | 553 |

Source: FAB Securities



2) Relative Valuation:

We have used local and international peers to value CBD and it is valued using the PB multiple. It is valued at a 2025 PB multiple of 1.4x in line with peers.

| Company | Market | P/B(x) | | PE (x) | | Yield (%) | |
|--------------------|----------|--------|-------|--------|-------|-----------|-------|
| | (USD Mn) | 2024F | 2025F | 2024F | 2025F | 2024F | 2025F |
| Dubai Islamic Bank | 14,933 | 1.4 | 1.3 | 8.6 | 9.5 | 6.1 | 5.9 |
| Emirates NBD | 38,605 | 1.2 | 1.1 | 6.1 | 6.8 | 5.1 | 5.2 |
| ADCB | 21,596 | 1.2 | 1.1 | 9.3 | 9.6 | 5.0 | 5.1 |
| MASQ | 11,889 | 1.3 | 1.2 | 6.8 | 7.1 | 6.9 | 6.9 |
| ADIB | 15,464 | 2.5 | 2.3 | 10.7 | 11.1 | 4.9 | 5.0 |
| Alinma Bank | 19,817 | 2.1 | 1.8 | 12.7 | 11.5 | 3.6 | 3.9 |
| Average | | 1.6x | 1.5x | 9.0x | 9.3x | 5.3% | 5.3% |
| Median | | 1.4x | 1.3x | 9.0x | 9.6x | 5.1% | 5.1% |
| Max | | 1.9x | 1.7x | 10.3x | 10.7x | 5.8% | 5.7% |
| Min | | 1.3x | 1.1x | 7.2x | 7.7x | 4.9% | 5.0% |

Source: FAB Securities



Research Rating Methodology:

| Rating | Upside/Downside potential |
|------------|---------------------------|
| BUY | Higher than +15% |
| ACCUMULATE | Between +10% to +15% |
| HOLD | Lower than +10% to -5% |
| REDUCE | Between -5% to -15% |
| SELL | Lower than -15% |

FAB Securities Contacts:

| Research Analyst Ahmad Banihani | +971-2-6161629 | ahmad.banihani@Bankfab.com | | |
|--|------------------------------------|----------------------------|--|--|
| Sales & Execution Abu Dhabi Head Office | | | | |
| Trading Desk | +971-2-6161700/1 +971-2-6161777 | Online Trading Link | | |
| Institutional Desk | +971-4-4245765 | | | |

DISCLAIMER

This report has been prepared by FAB Securities (FABS), which is authorised by the UAE Securities and Commodities Authority, licensing registration number 604002, and is a member of the Abu Dhabi Securities Exchange and Dubai Financial Market. The information, opinions and materials contained in this report are provided for information purposes only and are not to be used, construed, or considered as an offer or the solicitation of an offer or recommendation to sell or to buy or to subscribe for any investment security or other financial instrument. The information, opinions and material in this report have been obtained and derived from publicly available information and other sources considered reliable without being independently verified for their accuracy or completeness. FABS gives no representation or warranty, express or implied, as to the accuracy and completeness of information and opinions expressed in this report. Opinions expressed are current as of the original publication date appearing on the report only and the information, including the opinions contained herein, are subject to change without notice. FABS is under no obligation to update this report. The investments referred to in this report might not be suitable for all recipients. Recipients should not base their investment decisions on this report and should make their own investigations, and obtain independent advice, as appropriate. Any loss or other consequences arising from the uses of material contained in this report shall be the sole and exclusive responsibility of the recipient and FABS accepts no liability for any such loss or consequence. The value of any investment could fall as well as rise and the investor may receive less than the original amount invested. Some investments mentioned in this report might not be liquid investments, which could be difficult to realise in cash. Some investments discussed in this report could be characterised by high level of volatility, which might result in loss. FABS owns the intellectual property rights and any other material contained in this report. No part of this report may be reproduced, utilised or modified in any form either in whole or in part or by any electronic, mechanical or other means, now known or hereafter invented, including photocopying and recording, or stored in any retrieval system without the prior consent of FABS in writing. While utmost care has been taken to ensure that the information provided is accurate and correct, neither FABS, nor its employees shall, in any way, be responsible for the contents. By accepting this document, the recipient agrees he/she has read the above disclaimer and to be bound by the foregoing limitations/restrictions.